Brian M. Schmidt, DPM, and Laura Shin, DPM, PhD, shared strategies used to maintain access to care and regular physical exams for patients with diabetic foot complications amid COVID-19.
Emilyn Uy Alejandro, PhD, and Rochelle N. Naylor, MD, will discuss new insight into the heterogeneity of diabetes and how it translates to patient care.
Yehuda Handelsman, MD, Tina Costacou, PhD, and Sophia Zoungas, MBBS (Hons), PhD, FRACP, will examine the dynamics of weight and cardiovascular risk in type 1 diabetes. The symposium includes a debate on drugs to prevent cardiovascular disease.
“You could eat a diet of bacon and diet soda all day long and you’d manage your glucose really well. But that wouldn’t be good for your whole health,” said Holly Willis, PhD, RDN, LD.
“We have brought together the best and the brightest minds focused on diabetes research and diabetes care,” said ADA CEO Tracey D. Brown.
Hui Shao, MD, PhD, will discuss the financial implications these classes of agents, which have transformed diabetes care for individuals who also have cardiovascular disease, have brought to the health care system.
Shivani Agarwal, MD, MPH, Shakira Suglia, ScD, MS, and J. Frank Wharam, MD, MPH, will examine strategies to address risks influenced by social needs and to improve outcomes.
The digital diabetes care market will be worth upward of $700 million in 2022. Anne L. Peters, MD, and Kasia J. Lipska, MD, MHS, BS, will explore whether it is worth the cost.
Jennifer Sherr, MD, PhD, will highlight new glucagon formulations for treatment, and Nicole de Zoysa, DClinPsych, will review the impact of overcoming psychological obstacles on optimal hypoglycemia management.
The average ages of patients who are potentially eligible for pancreas transplantation and of potential organ donors are on the rise, but that is not the only challenge for this sector of the diabetes community, as Eelco J.P. de Koning, MD, PhD, will explain.